In the Phase II DREAMM-2 study, belantamab mafodotin, an anti-BCMA antibody–drug conjugate, has demonstrated single-agent activity and a manageable safety profile in patients with relapsed/refractory multiple myeloma who had received ≥3 lines of therapy and were refractory to an IMiD, a proteasome inhibitor, and an anti-CD38 antibody (n = 196) [26]. The gene discussed is CD38; the disease is plasma cell myeloma.